| Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies MA Nalls, C Blauwendraat, CL Vallerga, K Heilbron, S Bandres-Ciga, ... The Lancet Neurology 18 (12), 1091-1102, 2019 | 1942 | 2019 |
| Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences C Manzoni, DA Kia, J Vandrovcova, J Hardy, NW Wood, PA Lewis, ... Briefings in bioinformatics 19 (2), 286-302, 2018 | 848 | 2018 |
| Estimating the causal influence of body mass index on risk of Parkinson disease: a Mendelian randomisation study AJ Noyce, DA Kia, G Hemani, A Nicolas, TR Price, E De Pablo-Fernandez, ... PLoS medicine 14 (6), e1002314, 2017 | 177 | 2017 |
| Identification of candidate Parkinson disease genes by integrating genome-wide association study, expression, and epigenetic data sets DA Kia, D Zhang, S Guelfi, C Manzoni, L Hubbard, RH Reynolds, J Botía, ... JAMA neurology 78 (4), 464-472, 2021 | 151 | 2021 |
| Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome CS Storm, DA Kia, MM Almramhi, S Bandres-Ciga, C Finan, AD Hingorani, ... Nature communications 12 (1), 7342, 2021 | 106 | 2021 |
| System Genomics of Parkinson’s Disease Consortium; International Parkinson’s Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk … MA Nalls, C Blauwendraat, CL Vallerga, K Heilbron, S Bandres-Ciga, ... Lancet Neurol 18 (12), 1091-1102, 2019 | 102 | 2019 |
| Expanding Parkinson’s disease genetics: novel risk loci, genomic context, causal insights and heritable risk MA Nalls, C Blauwendraat, CL Vallerga, K Heilbron, S Bandres-Ciga, ... BioRxiv, 388165, 2019 | 99 | 2019 |
| The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease S Bandres‐Ciga, S Saez‐Atienzar, L Bonet‐Ponce, K Billingsley, D Vitale, ... Movement Disorders 34 (4), 460-468, 2019 | 87 | 2019 |
| Frequency of loss of function variants in LRRK2 in Parkinson disease C Blauwendraat, X Reed, DA Kia, Z Gan-Or, S Lesage, L Pihlstrøm, ... JAMA neurology 75 (11), 1416-1422, 2018 | 81 | 2018 |
| Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score H Iwaki, C Blauwendraat, MB Makarious, S Bandrés‐Ciga, HL Leonard, ... Movement Disorders 35 (5), 774-780, 2020 | 73 | 2020 |
| The Parkinson's disease Mendelian randomization research portal AJ Noyce, S Bandres‐Ciga, J Kim, K Heilbron, D Kia, G Hemani, A Xue, ... Movement Disorders 34 (12), 1864-1872, 2019 | 67 | 2019 |
| The genetic architecture of Parkinson disease in Spain: characterizing population‐specific risk, differential haplotype structures, and providing etiologic insight S Bandres‐Ciga, S Ahmed, MS Sabir, C Blauwendraat, ... Movement Disorders 34 (12), 1851-1863, 2019 | 62 | 2019 |
| Investigation of autosomal genetic sex differences in Parkinson's disease C Blauwendraat, H Iwaki, MB Makarious, S Bandres‐Ciga, HL Leonard, ... Annals of neurology 90 (1), 35-42, 2021 | 55 | 2021 |
| Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk MA Nalls, C Blauwendraat, CL Vallerga, K Heilbron, S Bandres-Ciga, ... BioRxiv, 388165, 2018 | 55 | 2018 |
| MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration R Simone, F Javad, W Emmett, OG Wilkins, FL Almeida, ... Nature 594 (7861), 117-123, 2021 | 50 | 2021 |
| Stratification of candidate genes for Parkinson’s disease using weighted protein-protein interaction network analysis R Ferrari, DA Kia, JE Tomkins, J Hardy, NW Wood, RC Lovering, ... BMC genomics 19, 1-8, 2018 | 50 | 2018 |
| Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease DA Kia, AJ Noyce, J White, D Speed, A Nicolas, IPDGC collaborators, ... Annals of neurology 84 (2), 191-199, 2018 | 50 | 2018 |
| Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at 16q11. 2 and MAPT H1 loci MPM Soutar, D Melandri, B O’Callaghan, E Annuario, AE Monaghan, ... Brain 145 (12), 4349-4367, 2022 | 42 | 2022 |
| Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease C Blauwendraat, DA Kia, L Pihlstrøm, Z Gan-Or, S Lesage, JR Gibbs, ... Neurobiology of aging 64, 159. e5-159. e8, 2018 | 37 | 2018 |
| Using Mendelian randomization to understand and develop treatments for neurodegenerative disease CS Storm, DA Kia, M Almramhi, NW Wood Brain communications 2 (1), fcaa031, 2020 | 18 | 2020 |
